Zhejiang Dayang Biotech Group Co
Zhe Jiang Dayang Biotech Group Co., Ltd. operates as a chemical raw material manufacturing company in China and internationally. The company offers inorganic chemicals, including potassium carbonate and chloride, ammonium chloride, and bicarbonate food and feed additives; industrial grade potassium carbonate and bicarbonate; and agricultural and industrial grade ammonium chloride. It also provide… Read more
Market Cap & Net Worth: Zhejiang Dayang Biotech Group Co (003017)
Zhejiang Dayang Biotech Group Co (SHE:003017) has a market capitalization of $360.17 Million (CN¥2.64 Billion) as of March 18, 2026. Listed on the SHE stock exchange, this China-based company holds position #14842 globally and #3941 in its home market, demonstrating a -5.53% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Zhejiang Dayang Biotech Group Co's stock price CN¥31.46 by its total outstanding shares 84000000 (84.00 Million).
Zhejiang Dayang Biotech Group Co Market Cap History: 2020 to 2026
Zhejiang Dayang Biotech Group Co's market capitalization history from 2020 to 2026. Data shows growth from $387.80 Million to $360.17 Million (2.74% CAGR).
Zhejiang Dayang Biotech Group Co Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Zhejiang Dayang Biotech Group Co's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.23x
Zhejiang Dayang Biotech Group Co's market cap is 0.23 times its annual revenue
8.83x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
3.34x
Zhejiang Dayang Biotech Group Co's market cap is 3.34 times its annual earnings
4.10x
Lower than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $387.80 Million | $678.34 Million | $91.61 Million | 0.57x | 4.23x |
| 2021 | $318.05 Million | $783.21 Million | $70.01 Million | 0.41x | 4.54x |
| 2022 | $214.85 Million | $1.06 Billion | $80.73 Million | 0.20x | 2.66x |
| 2023 | $270.31 Million | $919.45 Million | $50.01 Million | 0.29x | 5.41x |
| 2024 | $213.17 Million | $909.96 Million | $63.75 Million | 0.23x | 3.34x |
Competitor Companies of 003017 by Market Capitalization
Companies near Zhejiang Dayang Biotech Group Co in the global market cap rankings as of March 18, 2026.
Key companies related to Zhejiang Dayang Biotech Group Co by market ranking:
- Linde PLC (XETRA:LIN): Ranked #84 globally with a market cap of $187.60 Billion USD ( €182.76 Billion EUR).
- BASF SE NA O.N. (OTCQX:BFFAF): Ranked #461 globally with a market cap of $47.09 Billion USD.
- Shin-Etsu Chemical Co. Ltd (PINK:SHECF): Ranked #470 globally with a market cap of $46.17 Billion USD.
- A. Schulman Inc (PINK:SLMNP): Ranked #826 globally with a market cap of $23.93 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #84 | Linde PLC | XETRA:LIN | $187.60 Billion | €429.40 |
| #461 | BASF SE NA O.N. | OTCQX:BFFAF | $47.09 Billion | $53.46 |
| #470 | Shin-Etsu Chemical Co. Ltd | PINK:SHECF | $46.17 Billion | $24.66 |
| #826 | A. Schulman Inc | PINK:SLMNP | $23.93 Billion | $901.00 |
Zhejiang Dayang Biotech Group Co Historical Marketcap From 2020 to 2026
Between 2020 and today, Zhejiang Dayang Biotech Group Co's market cap moved from $387.80 Million to $ 360.17 Million, with a yearly change of 2.74%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥360.17 Million | +5.36% |
| 2025 | CN¥341.85 Million | +60.37% |
| 2024 | CN¥213.17 Million | -21.14% |
| 2023 | CN¥270.31 Million | +25.81% |
| 2022 | CN¥214.85 Million | -32.45% |
| 2021 | CN¥318.05 Million | -17.99% |
| 2020 | CN¥387.80 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Zhejiang Dayang Biotech Group Co was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $360.17 Million USD |
| MoneyControl | $360.17 Million USD |
| MarketWatch | $360.17 Million USD |
| marketcap.company | $360.17 Million USD |
| Reuters | $360.17 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.